Dipeptidylpeptidase-4 Inhibitors (Gliptins)

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Pharmacokinetics

• Publication date

  2010-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/11532980-000000000-00000PMID 20690781
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current Management Strategies for Coexisting Diabetes Mellitus and Obesity

  2012cited by this paper
• Vildagliptin

  2012cited by this paper
• Oral Antidiabetic Agents

  2012cited by this paper
• Sitagliptin

  2012cited by this paper
• Vildagliptin

  2012cited by this paper
• The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

  2010cited by this paper
• Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.

  2010cited by this paper
• Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2010cited by this paper
• Saxagliptin: A New Dipeptidyl Peptidase 4 Inhibitor for Type 2 Diabetes

  2010cited by this paper
• Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors

  2010cited by this paper
• Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes

  2010cited by this paper
• Addition of incretin therapy to metformin in type 2 diabetes.

  2010cited by this paper
• Effect of linagliptin (BI 1356) on the steady-state pharmacokinetics of simvastatin.

  2010cited by this paper
• Reaching HbA1c Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs

  2010cited by this paper
• Sitagliptin

  2010cited by this paper
• Standards of Medical Care in Diabetes—2010

  2010cited by this paper
• Adiponectin and Lipoprotein Particle Size

  2010cited by this paper
• The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

  2009cited by this paper
• Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.

  2009cited by this paper
• Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  2009cited by this paper
• Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions

  2009cited by this paper
• Multiple Doses of Sitagliptin, a Selective DPP‐4 Inhibitor, Do Not Meaningfully Alter Pharmacokinetics and Pharmacodynamics of Warfarin

  2009cited by this paper
• Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

  2009cited by this paper
• Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes*

  2009cited by this paper
• Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

  2009cited by this paper
• Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes.

  2009cited by this paper
• Rhabdomyolysis Caused by a Potential Sitagliptin‐Lovastatin Interaction

  2009cited by this paper
• Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

  2009cited by this paper
• Efficacy and safety of adding the dipeptidyl peptidase‐4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double‐blind, placebo‐controlled study

  2009cited by this paper
• Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

  2009cited by this paper
• Vildagliptin in clinical practice: a review of literature

  2009cited by this paper
• Effect of Sitagliptin on the Pharmacokinetics of Simvastatin

  2009cited by this paper
• Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

  2009cited by this paper
• Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  2009cited by this paper
• Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.

  2009cited by this paper
• Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?

  2009cited by this paper
• Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

  2009cited by this paper
• Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

  2009cited by this paper
• Drug evaluation: Vildagliptin-metformin single-tablet combination

  2009cited by this paper
• DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

  2009cited by this paper
• Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

  2009cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

  2009cited by this paper
• Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

  2009cited by this paper
• Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.

  2008cited by this paper
• Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use

  2008cited by this paper
• Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea *

  2008cited by this paper
• Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

  2008cited by this paper
• Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

  2008cited by this paper
• New combination treatments in the management of diabetes: focus on sitagliptin – metformin

  2008cited by this paper
• Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects.

  2008cited by this paper
• Janumet™: a combination product suitable for use in patients with Type 2 diabetes

  2008cited by this paper
• Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects

  2008cited by this paper
• Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

  2008cited by this paper
• Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects.

  2008cited by this paper
• AMH (Australian Medicines Handbook, 2007 Edition)

  2008cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• Postmenopausal Hormone Therapy for Disease Prevention: Have We Learned Any Lessons from the Past?

  2008cited by this paper
• Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug

  2007cited by this paper
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).

  2007cited by this paper
• Pharmacokinetic Interactions with Thiazolidinediones

  2007cited by this paper
• Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.

  2007cited by this paper
• Multiple‐Dose Administration of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Does Not Alter the Single‐Dose Pharmacokinetics of Rosiglitazone in Healthy Subjects

  2007cited by this paper
• Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

  2007cited by this paper
• Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects*

  2007cited by this paper
• Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide

  2007cited by this paper
• Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects*

  2007cited by this paper
• Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study *

  2007cited by this paper
• Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers

  2007cited by this paper
• Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

  2007cited by this paper
• Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein

  2007cited by this paper
• Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary

  2007cited by this paper
• The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

  2007cited by this paper
• Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

  2007cited by this paper
• PI‐65

  2006cited by this paper
• Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

  2006cited by this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents

  2005cited by this paper
• Drug Interactions of Clinical Importance with Antihyperglycaemic Agents : An Update.

  2005cited by this paper
• Cytochrome P450 Drug Interactions Within the HMG-CoA Reductase Inhibitor Class

  2003cited by this paper
• Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

  2002cited by this paper
• Oral Antidiabetic Agents

  1998cited by this paper
• Clinical Pharmacokinetics of Metformin

  1996cited by this paper
• Antihyperglycaemic Agents

  1995cited by this paper
• Oral antidiabetic agents.

  1970cited by this paper

• Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus

  2025cites this paper
• A Data Mining Approach on Polypharmacy and Drug-drug Interactions of Common Diabetes Medications.

  2025cites this paper
• Korean Red Ginseng Extract Powder Mitigates Fasting And Postprandial Hyperglycemia in Type 2 Diabetic Mice

  2024cites this paper
• Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist

  2024cites this paper
• Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

  2024cites this paper
• Computational approaches for lead compound discovery in dipeptidyl peptidase-4 inhibition using machine learning and molecular dynamics techniques

  2024cites this paper
• Antiretrovirals and frequently prescribed medications in people living with HIV: Potential drug-drug interactions detected by three online-databases

  2024influential citation
• Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM).

  2024cites this paper
• Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy

  2023cites this paper
• Cost-effective Analysis of Prescribed Oral Hypoglycemic Agents amongst Pre-obese and Obese Diabetic Patients in a Tertiary Care Hospital in Odisha

  2023cites this paper
• DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature

  2023cites this paper
• The Effects of the New Therapeutic Treatments for Diabetes Mellitus on the Male Reproductive Axis

  2022cites this paper
• In Vivo and In Vitro Comparison of the DPP-IV Inhibitory Potential of Food Proteins from Different Origins after Gastrointestinal Digestion

  2022cites this paper
• Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter.

  2021cites this paper
• Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors

  2021cites this paper
• An electrochemical molecularly imprinted sensor based on CuBi2O4/rGO@MoS2 nanocomposite and its utilization for highly selective and sensitive for linagliptin assay.

  2021cites this paper
• Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics

  2021cites this paper
• Hydrogenation involved in the chemical–biological synthesis of miglitol: effect of biological impurities on catalytic activity and catalyst reuse

  2021cites this paper
• DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients

  2020cites this paper
• Dipeptidyl Peptidase-4 deficiency effectively protects the brain and neurological function in rodent after acute Hemorrhagic Stroke

  2020cites this paper
• The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs.

  2020cites this paper
• Recurrent hyperglycemic hyperosmolar state after re-administration of dose-reduced ceritinib, an anaplastic lymphoma kinase inhibitor

  2020cites this paper
• Sensitive detection of quinoline-derivatized sitagliptin in small volumes of human plasma by MALDI-TOF mass spectrometry.

  2020cites this paper
• Evaluation of chitosan/eudragit hybrid coating over cubic DNA nanospheres with superior stability and therapeutic outcomes

  2019cites this paper
• Chitosan-coated rectangular DNA nanospheres for better outcomes of anti-diabetic drug

  2019cites this paper
• Management of diabetes mellitus in patients undergoing liver transplantation

  2019cites this paper
• Vildagliptine protects SH-SY5Y human neuron-like cells from Aβ 1–42 induced toxicity, in vitro

  2019cites this paper
• A Clinical Drug‐Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin

  2019cites this paper
• Design, synthesis and evaluation of DNA nanocubes as a core material protected by the alginate coating for oral administration of anti-diabetic drug

  2019cites this paper
• The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect

  2019cites this paper
• DNA scaffold nanoparticles coated with HPMC/EC for oral delivery.

  2019cites this paper
• TRANSPORTADORES CELULARES DE DROGAS. EL VIAJE DE LOS ANTIDIABÉTICOS ORALES POR EL ORGANISMO

  2018cites this paper
• Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review

  2018cites this paper
• The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin

  2018cites this paper
• Kombiglyze (metformin and saxagliptin)‐induced hepatotoxicity in a patient with non‐alcoholic fatty liver disease

  2018cites this paper
• DPP-4 enzyme deficiency protects kidney from acute ischemia-reperfusion injury: role for remote intermittent bowel ischemia-reperfusion preconditioning

  2017cites this paper
• KCNQ1 gene polymorphism is associated with glycaemic response to treatment with DPP-4 inhibitors.

  2017cites this paper
• Non‐insulin anti‐diabetic drugs: An update on pharmacological interactions

  2017cites this paper
• Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes

  2017cites this paper
• Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose?

  2017cites this paper
• Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.

  2017cites this paper
• Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes

  2017cites this paper
• In vitro evaluation of potential transporter‐mediated drug interactions of evogliptin

  2017cites this paper
• Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study

  2016cites this paper
• Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction

  2016cites this paper
• Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

  2016cites this paper
• Grape powder attenuates the negative effects of GLP-1 receptor antagonism by exendin-3 (9-39) in a normoglycemic mouse model.

  2016cites this paper
• Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas

  2016cites this paper
• Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study

  2016cites this paper
• Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes

  2016cites this paper
• Clinically and pharmacologically relevant interactions of antidiabetic drugs

  2016cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor

  2016cites this paper
• Gliptins in managing diabetes - Reviewing computational strategy.

  2016cites this paper
• Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus

  2016cites this paper
• A SIMPLE AND SENSITIVE STABILITY-INDICATING HPTLC ASSAY METHOD FOR THE DETERMINATION OF LINAGLIPTIN

  2016cites this paper
• Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects

  2015cites this paper
• Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

  2015cites this paper
• Dipeptidyl Peptidase-4 Greatly Contributes to the Hydrolysis of Vildagliptin in Human Liver

  2015cites this paper
• DPP-4 inhibitors: focus on safety

  2015cites this paper
• CYP3A4 Mediates Oxidative Metabolism of the Synthetic Cannabinoid AKB-48

  2015cites this paper
• Incidence of potential drug-drug interactions with antidiabetic drugs.

  2015cites this paper
• Antidiabetic therapy in post kidney transplantation diabetes mellitus.

  2015cites this paper
• Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

  2015cites this paper
• Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

  2015cites this paper
• A review of gliptins for 2014

  2015cites this paper
• An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus

  2015cites this paper
• Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

  2015cites this paper
• Recent Pharmacokinetic Studies in Combination Therapies for Diabetes and Related Vascular Complications.

  2015cites this paper
• Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials.

  2015cites this paper
• Role of Sitagliptin-Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes Mellitus-An Overview

  2015cites this paper
• Hoofdstuk 9 (Farmaco)therapie van diabetes mellitus type 2 bij de oudere patiënt

  2015cites this paper
• Comparación de la eficacia de los

  2015cites this paper
• Alteration of pharmacokinetics of grepafloxacin in type 2 diabetic rats.

  2014cites this paper
• Alogliptin for the treatment of Type 2 diabetes

  2014cites this paper
• Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.

  2014cites this paper
• Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus

  2014cites this paper
• Sixteen-years of clinically relevant dipeptidyl peptidase-IV (DPP-IV) inhibitors for treatment of type-2 diabetes: a perspective.

  2014cites this paper
• Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.

  2014cites this paper
• Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats

  2014cites this paper
• Diltiazem Reduces Mortality and Breakdown of ATP in Red Blood Cell Induced by Isoproterenol in a Freely Moving Rat Model in Vivo

  2014cites this paper
• Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

  2014cites this paper
• Evolving Metformin Treatment Strategies in Type-2 Diabetes: From Immediate-Release Metformin Monotherapy to Extended-Release Combination Therapy

  2014cites this paper
• The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors

  2014cites this paper
• DPP-4 inhibitors: pharmacological differences and their clinical implications

  2014cites this paper
• Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors

  2014cites this paper
• Linagliptin for the treatment of Type 2 diabetes

  2014cites this paper
• Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans

  2014cites this paper
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

  2013cites this paper
• Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin

  2013cites this paper
• Linagliptin provides effective, well‐tolerated add‐on therapy to pre‐existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes

  2013cites this paper
• Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes

  2013cites this paper
• A review of the efficacy and safety of oral antidiabetic drugs

  2013cites this paper
• GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?

  2013cites this paper
• Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.

  2013cites this paper
• Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers

  2013cites this paper
• Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation

  2013cites this paper
• Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction

  2013influential citation
• Saxagliptin overview: special focus on safety and adverse effects

  2013cites this paper
• Functional alterations of intestinal P-glycoprotein under diabetic conditions.

  2013cites this paper